Related Experiment Video
Updated: Jul 8, 2025

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
Published on: January 26, 2019
Disagreement FDA and EMA on RSV Maternal Vaccination: Possible Consequence for Global Mortality
Joukje E Willemsen1,2, José A M Borghans1, Louis J Bont2
1From the Centre for Translational Immunology, University Medical Centre Utrecht, Utrecht, the Netherlands.
Abstract:
The European Medicines Agency and the US Food and Drug Administration have recently approved a maternal vaccine for respiratory syncytial virus. The US Food and Drug Administration limits vaccination to later in pregnancy. Mathematical modeling demonstrates that this vaccination window may reduce the global mortality impact of the vaccine by 12%. Policymakers should carefully consider vaccine risks and benefits to safeguard vulnerable infants effectively.
More Related Videos
Related Concept Videos
Vaccinations
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

